VivoSim Labs

Update in progress

VIVS (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

VivoSim Labs, Inc. is a pharmaceutical and biotechnology services company that tests drugs and candidates in 3D human liver and intestinal tissue models. It provides toxicology insights, mechanism-of-action elucidation, and bespoke investigational toxicology services using novel approach methodologies. The firm offers predictive liver toxicity screening, intestinal side-effect profiling, and high-throughput, bioprinted, flow/stretch-capable tissue platforms. Formerly Organovo Holdings, it was renamed in 2025, and is based in San Diego, CA.

Company score

Sentiment: 0.20; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.17; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.18; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.04; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.12; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.16; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive